Proteinuria in canine patients with lymphoma

Bella, Annamaria Di; Maurella, Cristiana; Cauvin, Andria; Schmidt, Julien; Tapia, B. B.; North, Susan M

doi:10.1111/jsap.12004.x

Cited by 10 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of proteinuria in treatment dogs tended to be higher than the control dogs and despite the range of neoplasia types represented in this study, was comparable to the prevalence of proteinuria in dogs with lymphoma or osteosarcoma previously reported (9-25%). d , 32 Group 2a dogs treated with toceranib phosphate had significantly higher SBP after the initiation of TKI treatment, which appears consistent with previous reports in both dogs b and people. [3][4][5][6][7][8][9] In a study of 20 human patients receiving sorafenib, mean SBP increased from 131 to 151 mmHg, with 75% of patients experiencing an increase of >10 mmHg and 60% increasing >20 mmHg.…”

Section: Discussionsupporting

confidence: 89%

“…There was no statistical difference in the median UPC of control dogs and treatment dogs at baseline. The prevalence of proteinuria in treatment dogs tended to be higher than the control dogs and despite the range of neoplasia types represented in this study, was comparable to the prevalence of proteinuria in dogs with lymphoma or osteosarcoma previously reported (9–25%) , …”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs

Tjostheim

Stepien

Markovic

et al. 2016

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundSystemic hypertension and proteinuria are established adverse effects of tyrosine kinase inhibitor treatment in people.ObjectiveThe objective of this study was to investigate changes in systolic blood pressure and the incidence of proteinuria secondary to treatment with toceranib phosphate in dogs with cancer.AnimalsTwenty‐six control dogs and 30 dogs with cancer were evaluated for the first part of the study (baseline characteristics). For the second part (effect of toceranib phosphate treatment), 48 client‐owned dogs were evaluated, including 20 control dogs and 28 dogs with various types of neoplasia.MethodsProspective cohort study. Client‐owned healthy control dogs and dogs with cancer were enrolled. Blood pressure and urine protein:creatinine ratios were measured before treatment and 2 weeks after initiation of toceranib phosphate treatment.ResultsSystolic blood pressure was significantly (P = 0.0013) higher in previously normotensive treatment dogs after initiation of treatment with toceranib phosphate (152 mmHg ± 19) compared to baseline (136 mmHg ± 14). 37% of treated dogs developed SBP ≥ 160 mmHg. The prevalence of systemic hypertension (37%) and proteinuria (21%) at baseline in treatment dogs did not differ from that of age‐matched healthy controls (15% [P = 0.13] and 0% [P = 0.069], respectively).Conclusions and Clinical ImportanceToceranib phosphate treatment might result in increased systolic blood pressures in dogs. Systemic hypertension should be considered a potential adverse effect of this drug in dogs. Systemic hypertension and proteinuria were detected at clinically relevant frequencies in the dogs with cancer before antineoplastic therapies suggesting that monitoring of these variables might be warranted in this population.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 85%

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs

Tjostheim

Stepien

Markovic

et al. 2016

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…, Di Bella et al . ). Although it would have been interesting to correlate the magnitude of persistent proteinuria with specific cancer diagnoses and even cancer stage, this was not attempted in the present study due to the large number of confounding patient variables and the limited number of cancer diagnoses other than cutaneous mast cell tumour and lymphoma.…”

Section: Discussionmentioning

confidence: 97%

“…Also, it has been demonstrated that dogs with lymphoma are more likely to be proteinuric than age‐matched controls (Di Bella et al . ), as is the case in dogs with mammary carcinoma (Crivellenti et al . ).…”

Section: Introductionmentioning

confidence: 86%

Prevalence of proteinuria in a canine oncology population

Prudic

Saba

Lourenço

et al. 2018

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…Neoplasia is one of several known causes of proteinuria in dogs. Potential factors contributing to the development of proteinuria in dogs with cancer include decreased renal blood flow, injury induced by products of the tumor cells, and deposition of antigen–antibody immune complexes [ 59 , 60 , 61 ]. The degree of proteinuria is generally mild, typically requiring monitoring rather than immediate intervention [ 59 ].…”

Section: Discussionmentioning

confidence: 99%

Alterations of Serum Biochemical and Urinary Parameters in a Canine Population before and after Intravenous Contrast Administration

Cagnasso

Bruno

Bellino

et al. 2021

Veterinary Sciences

View full text Add to dashboard Cite

Intravenous iodinated contrast (IVIC) medium is routinely administered to dogs. Scattered information exists regarding the serum biochemical or urinary profiles associated with the administration of IVIC in dogs. The aim of the study was to describe, compare, and discuss from the perspective of previous studies the alterations in serum biochemical and urinary parameters before (T0) and within one week (T1) of the IVIC administration during routine computed tomography (CT) scan evaluation of 22 dogs. Mature dogs presenting for CT scan evaluation for preoperative oncology staging/surgical planning were included. T1 evaluation was performed within one week of IVIC administration. Statistically significant differences in serum total protein, albumin, chloride, calcium, and phosphorus concentrations, urine protein to creatinine ratio, and urine specific gravity were found between T1 and T0. At T1, the serum creatinine concentration was within reference ranges in all dogs but one. An increase in the urine protein to creatinine ratio was observed in four samples, one of which was non-proteinuric at T0. Changes in biochemistry and urine parameters between T0 and T1 were not considered clinically significant.

show abstract

Proteinuria in canine patients with lymphoma

Abstract: Mild proteinuria is a common finding in dogs with lymphoma. The clinical impact of the proteinuria is probably low.

Cited by 10 publications

References 20 publications

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs

Prevalence of proteinuria in a canine oncology population

Alterations of Serum Biochemical and Urinary Parameters in a Canine Population before and after Intravenous Contrast Administration

Contact Info

Product

Resources

About